According to Zacks, “Collegium Pharmaceutical Inc. is a specialty pharmaceutical company. It develops and commercializes prescription and over-the-counter pharmaceuticals for the treatment of central nervous system, respiratory and skin related disorders. The Company’s product candidate consists of COL-195, COL-196, COL-171, COL-003 and COL-172 which are in different clinical trial. It developed a formulation platform technology, DETERx, for the treatment of chronic pain. Collegium Pharmaceutical Inc. is based in CUMBERLAND, United States. “
A number of other research firms have also weighed in on COLL. Piper Jaffray Cos. set a $23.00 target price on shares of Collegium Pharmaceutical and gave the stock a buy rating in a report on Thursday, August 11th. Needham & Company LLC reissued a buy rating and issued a $30.00 price target on shares of Collegium Pharmaceutical in a research note on Wednesday, September 14th. Gabelli began coverage on shares of Collegium Pharmaceutical in a research note on Tuesday, September 13th. They issued a buy rating and a $25.00 price target for the company. Finally, Jefferies Group reissued a buy rating on shares of Collegium Pharmaceutical in a research note on Thursday, September 22nd. One research analyst has rated the stock with a hold rating and six have issued a buy rating to the company. The company has a consensus rating of Buy and an average target price of $27.60.
Shares of Collegium Pharmaceutical (NASDAQ:COLL) opened at 17.45 on Wednesday. The company’s 50 day moving average is $13.94 and its 200 day moving average is $14.53. Collegium Pharmaceutical has a 52-week low of $8.24 and a 52-week high of $30.58. The firm’s market cap is $410.56 million.
Collegium Pharmaceutical (NASDAQ:COLL) last posted its earnings results on Wednesday, August 10th. The specialty pharmaceutical company reported ($1.05) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.76) by $0.29. Analysts anticipate that Collegium Pharmaceutical will post ($3.86) earnings per share for the current year.
In other Collegium Pharmaceutical news, Director John A. Fallon acquired 2,375 shares of the business’s stock in a transaction dated Friday, August 12th. The stock was bought at an average price of $10.59 per share, with a total value of $25,151.25. Following the purchase, the director now owns 2,375 shares of the company’s stock, valued at $25,151.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. 37.93% of the stock is currently owned by insiders.
Large investors have recently made changes to their positions in the stock. Nationwide Fund Advisors boosted its stake in shares of Collegium Pharmaceutical by 73.3% in the second quarter. Nationwide Fund Advisors now owns 8,665 shares of the specialty pharmaceutical company’s stock worth $103,000 after buying an additional 3,665 shares during the period. Alliancebernstein L.P. acquired a new stake in shares of Collegium Pharmaceutical during the second quarter worth about $122,000. Royal Bank of Canada boosted its stake in shares of Collegium Pharmaceutical by 2.7% in the second quarter. Royal Bank of Canada now owns 11,600 shares of the specialty pharmaceutical company’s stock worth $137,000 after buying an additional 300 shares during the period. Rhumbline Advisers acquired a new stake in shares of Collegium Pharmaceutical during the second quarter worth about $143,000. Finally, A.R.T. Advisors LLC acquired a new stake in shares of Collegium Pharmaceutical during the second quarter worth about $148,000. 61.98% of the stock is owned by institutional investors.
About Collegium Pharmaceutical
Collegium Pharmaceutical, Inc is a specialty pharmaceutical company. The Company is developing and planning to commercialize abuse-deterrent products that include its DETERx platform technology for the treatment of chronic pain and other diseases. The Company’s lead product candidate, Xtampza ER (Xtampza) is an abuse-deterrent, extended-release, oral formulation of oxycodone, opioid medication.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Collegium Pharmaceutical Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Collegium Pharmaceutical Inc. and related companies with MarketBeat.com's FREE daily email newsletter.